<DOC>
	<DOCNO>NCT00002300</DOCNO>
	<brief_summary>To compare effect megestrol acetate placebo body weight , anorexia , cachexia , calorie intake , nutritional parameter patient confirm diagnosis AIDS . To characterize dose response relation weight gain . To determine whether megestrol acetate relative placebo improve perception well-being among AIDS patient cachexia . To evaluate megestrol acetate 's effect immune function via skin test reactivity , T4/T8 ratio , total lymphocyte .</brief_summary>
	<brief_title>A Study Different Doses Megestrol Acetate Patients With AIDS Who Have Anorexia Malnutrition</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Cachexia</mesh_term>
	<mesh_term>Megestrol</mesh_term>
	<mesh_term>Megestrol Acetate</mesh_term>
	<criteria>Inclusion Criteria Patient must : Confirmed diagnosis AIDS ( CDC definition ) . Documented weight loss anorexia . Life expectancy = &gt; 20 week . The perception weight loss detriment wellbeing . Ability provide inform consent , read write English . Prior Medication : Allowed : Ganciclovir . Exclusion Criteria Coexisting Condition : Patients follow exclude : Dementia evidence mental incompetence would preclude compliance protocol . Diarrhea define 5 watery stool per day least 7 day . Active uncontrolled systemic infection start treatment . ( Patients may enter least 2 week acute infection . ) Clinical radiologic evidence ascites pleural effusion . Concurrent Medication : Excluded : Therapy design treat underlie HIV infection may major impact appetite and/or weight gain . Patients start zidovudine ( AZT ) within eight week . ( Patients may previously treat AZT fail may currently receive AZT least 8 week . ) Patients follow exclude : Obstruction food intake impair digestive/absorptive function . Contraindications highdose megestrol acetate ( poorly control hypertension heart failure deep vein thrombosis ) . Inability consent available close followup . Active systemic infection start treatment . Patients may start therapy design treat underlie HIV infection may major impact appetite and/or weight gain . Clinical radiologic evidence ascites pleural effusion . Patients may start therapy design treat underlie HIV infection may major impact appetite and/or weight gain . Patients hospitalize suffered exacerbation illness associate weight loss within past 2 week exclude . Menstruating female patient exclude . Prior Medication : Excluded : Corticosteroids . Anabolic steroid . Marijuana . Megestrol acetate . Patients start zidovudine ( AZT ) within 8 week . ( Patients may previously treat AZT fail may currently receive AZT least 8 week . ) History substance abuse questionable current future abstinence .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>T-Lymphocytes</keyword>
	<keyword>Megestrol</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Anorexia</keyword>
	<keyword>Cachexia</keyword>
</DOC>